Alex Kelly

"Being added to the Russell 2000 Index broadens our visibility with institutional investors at a pivotal time for Precision BioSciences," said Alex Kelly, Chief Financial Officer of Precision BioSciences. "We are advancing two wholly owned clinical programs, PBGENE-HBV in chronic hepatitis B and PBGENE-DMD in Duchenne muscular dystrophy, with a cash runway supporting our operations through 2028." Read the full release here, loom.ly/Qxmv0lE #PrecisionBioSciences #Russell2000 $DTIL

Join us on Monday, November 3, at 11 am ET for a Precision BioSciences Virtual Symposium! The company's lead muscle program, PBGENE-DMD, represents the first in vivo gene editing therapy designed to restore functional dystrophin protein and improve long-term muscle function for patients with Duchenne Muscular Dystrophy (DMD). DMD is a rare, life-limiting disease that affects more than 15,000 individuals in the United States and many more globally. Current therapies offer only limited benefit. PBGENE-DMD has demonstrated significant and sustained improvement in muscle strength and performance in preclinical models by restoring the body’s ability to produce a near full-length dystrophin protein. This program has the potential to deliver a one-time, durable treatment that could redefine the DMD treatment landscape. Virtual Event Details— Date: Monday, November 3, 2025 Time: 11:00 AM Eastern Time Moderator: Cassie Gorsuch, PhD, Chief Scientific Officer, Precision BioSciences Featuring: Pat Furlong, President, Parent Project Muscular Dystrophy, and Aravindhan Veerapandiyan, M.D. (Dr. Panda), Associate Professor of pediatrics in the Division of Pediatric Neurology and DMD clinical investigator at the University of Arkansas for Medical Sciences at Arkansas Children’s Hospital Discussion Topics • The unmet medical need in Duchenne Muscular Dystrophy • The science behind ARCUS gene editing technology • Precision BioSciences’ roadmap toward IND and CTA filings in 2025 • The path to anticipated clinical data in 2026 This event will offer a detailed look at the science, mission, and future vision driving PBGENE-DMD and how Precision BioSciences is advancing gene editing to deliver meaningful, long-term impact for patients and families affected by DMD. Register to join at the link below! youtube.com/live/7l_ktz8JIEM… #PrecisionBioSciences #GeneEditing #DuchenneMuscularDystrophy #PBGENEDMD $DTIL

Standing together in red for #WorldDuchenneAwarenessDay, the Precision BioSciences team proudly supports the global fight against Duchenne muscular dystrophy and reaffirms our commitment to advancing hope through groundbreaking gene editing solutions. Learn more about PBGENE-DMD, Precision’s development program for the treatment of DMD, at our website! loom.ly/tcqMFgQ #CureDuchenne #SupportDuchenne #DMD #WDAD

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update! ✅ Announced first in vivo clinical validation for ARCUS gene editing across two distinct programs including wholly owned PBGENE-HBV and partnered program ECUR-506 ✅ Commenced Phase 1 ELIMINATE-B clinical trial for PBGENE-HBV, the first gene editing technology studied for Hepatitis B, in the fourth quarter of 2024 ✅ Demonstrated PGENE-HBV was safe and well tolerated with substantial antiviral activity measured by reduction of Hepatitis B surface antigen after only one administration at lowest dose level; Subsequent doses of PBGENE-HBV to follow with data expected throughout 2025 - ✅ Announced complete clinical response in first infant dosed by partner iECURE in ongoing Phase 1/2 clinical trial in Ornithine Transcarbamylase (OTC) Deficiency - ✅ Anticipated cash runway into the second half of 2026 is expected to enable achievement of key Phase 1 clinical inflection points across both wholly owned in vivo gene editing programs - Let Chief Financial Officer, Alex Kelly, tell you what you need to know. For more info, visit loom.ly/dR4mqyE. #GeneEditing #Biotech #DTIL

Precision receives $13 Million in proceeds from Imugene Limited convertible note maturity. This further reinforces Precision's expected cash runway into 2H 2026. loom.ly/B7R3CFo #GeneEditing $DTIL

World-Class Clinical Investigators added to Precision’s SAB as PBGENE-HBV Program Nears Clinical Readiness! Together, they bring immense expertise as we expect to submit the IND &/or CTA applications for PBGENE-HBV later this year. Learn More 👉 loom.ly/JGM0mXw $DTIL

We're honored to have Wendy Shoop, PhD, represent the Precision team at the United Mitochondrial Disease Foundation’s (UMDF) Mitochondrial Medicine 2024 Conference! loom.ly/f8wGqgY #GeneEditing #MitoMed24 #DTIL

Our team had a great time attending the @HepBFoundation's Annual Gala supporting #HBV awareness and honoring continued progress towards potential cures! We’re honored to advocate for this community and are hopeful for a momentous year ahead in #hepatitis B treatments. #DTIL

Tomorrow, Wendy Shoop, PhD, will be presenting data for our PBGENE-PMM program targeting m.3243-associated primary mitochondrial myopathy at the Mitochondrial Medicine – Therapeutic Development Annual Conference. #MitoMed24 #DTIL

Exciting news from iECURE! Their gene editing therapy ECUR-506 received UK approval for a clinical trial to treat OTC deficiency in infants. This CTA approval provides further regulatory support for ARCUS, our in vivo gene editing platform. #genediting bit.ly/3Tz76Od

#JPM News: We’ve completed a deal with @TGTherapeutics to develop azer-cel for autoimmune diseases. The deal extends our cash runway into 1H 2026 & funds our wholly owned PBGENE-HBV & PBGENE-PMM in vivo gene editing programs through Phase I Clinical Data. bit.ly/48IqY63

Precision’s Wendy Shoop, Ph.D., & @univmiami’s @Carlos_T_Moraes recently spoke with @BioWorld about the latest @NatMetabolim publication on mitoARCUS and our #investigational approach to primary mitochondrial myopathy. Read more from their conversation: bit.ly/48g3Bk6

We’re excited to share that our late-breaking abstract detailing a potentially curative strategy for chronic hepatitis B was accepted for presentation at the @AASLDtweets Liver Meeting on Nov. 13. We look forward to seeing you in Boston! #TLM23

This #MitoAwarenessWeek, we’re proud of advances made with our ARCUS gene editing platform, which can specifically edit mutant mitochondrial genomes, targeting primary mitochondrial myopathies. The simplicity of our technology is one way ARCUS is unique from other platforms.

It's all about the cut, size and simplicity. These three key features differentiate ARCUS from other gene editing tools. Learn more about how our ARCUS #geneediting platform drives defined outcomes here: bit.ly/45Fj8cj

Exciting news! Our late-breaking abstract featuring new preclinical data for our PBGENE-DMD program for the potential treatment of #Duchenne muscular dystrophy has been accepted for oral presentation on May 19 at #ASGCT23: bit.ly/41EKr4e @ASGCTherapy

Precision CEO, Michael Amoroso will present a corporate update at the @jpmorgan Health Care Conference taking place virtually January 10-13. Precision CSO, Derek Jantz, CFO, @JAlexKelly, and CMO, Alan List, will also join Michael for Q&A.>> bit.ly/3pPGn0O #JPM22 #JPM2022